期刊
JOURNAL OF CELLULAR PHYSIOLOGY
卷 234, 期 10, 页码 18262-18271出版社
WILEY
DOI: 10.1002/jcp.28458
关键词
CD8AP17s aptamer; chitosan; PLGA; tacrolimus
资金
- Mashhad University of Medical Sciences, Mashhad, Iran [930661]
Tacrolimus (TAC) acts as an inhibitor of calcineurin, which inhibits the production of interleukin-2. In this study, we aimed to design a targeted delivery platform with poly (lactide-co-glycolide; PLGA) nanoparticles modified with chitosan (CS) and CD8AP17s aptamer (Apt). MOLT-4 cells as CD8 positive and JURKAT cells as CD negative were adopted to investigate the efficacy of the proposed delivery system in vitro. The particle size and Zeta potential of the TAC-PLGA-CS-Apt nanocomplex were 345nm and 13.7mV, respectively. Release study showed an efficient TAC release from complex in citrate buffer (pH 5.5). The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed that TAC-PLGA-CS-Apt nanocomplex was highly selective toward MOLT-4 cells. Complex increased the cellular uptake of TAC in MOLT-4 cells (target) while reducing its cytotoxicity in JURKAT cells (nontarget). Our study showed that complex nanoconjugate could efficiently deliver TAC into MOLT-4 cells as a model of cytotoxic T cell and it could be considered as a potential candidate for TAC delivery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据